Dave,
I've given up worrying about Bay Street research coverage, its too oriented to retail investors and what we need to make serious money is institutions buying big chunks of this and holding it. Unfortunately, the kind of retail investor that gets tuned into a stock by a brokerage report will sell as easily as they buy. They don't always lead to long-term price appreciation.
For a smaller company, and DMX is tiny, the most we could expect is a couple of weeks of interest from a brokerage as the brokers touted the stock to their clients. And we all know only too well why that won't happen.
On that note, am I the only one who has noticed that REK has avoided paying underwriting fees to even second-tier firms like Yorktown but is giving an 8% cut to a short seller calling themselves a venture capitalist? Seriously, the more I think about it, the less sense it makes. What's her deal? At least we might have gotten a quick write-up from a broker (I'm assuming that REK learned her lesson from the last fiasco).
[BTW - I never congratulated those of you who sniffed out the fact that Acqua aren't venture capitalists - and if anyone's in doubt, this is NOT how VCs work.]
I might be sounding grumpy, but I'm not down on the company at this point, however, I do have real questions about the Acqua deal (and historically weak management).
The good news is that now that FDA approval looks like it might happen in my lifetime, then DMX may post some material sales data (as the UK is waste of time so far). Actual cash flow will likely draw the attention of institutions, as it will give them something to model (maybe the can ask Wolf for tips!) and we might get some brand name investors.
If this happens soon enough, DMX might not get booted out of the S&P/TSE Composite Index (if DMX goes, it will likely be in the third wave of deletions scheduled for December).
I have questions for anyone with the time/inclination to respond:
What's the likelihood that the patent will be extended in the various markets?
Also, I'm not clear on where they are with WF10 trials, can anyone explain that?
What's the status of the toe fungus project? |
